CCR7 and neoplasm: We evaluated the T cell subsets, including CD3+CD4+CD8− (Th) cells, CD3+CD4−CD8+ (cytotoxic T lymphocytes (CTLs)), CD45RA+/CCR7+ (naive T) cells, CD45RA−/CCR7+ (central memory T) cells, CD45RA−/CCR7− (effector memory T) cells and CD45RA+/CCR7− (terminally differentiated effector T) cells for all the patients before infusion and analyzed the correlation between T cell subset frequencies and CT041 anti-tumor activity in 28 patients with GC.